CNTB Stock Catalyst: Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart

Sep 30, 2026 · 7:03am ET

The study focused on Rademikibart as an add-on treatment for acute exacerbations in adults with COPD and Type 2 inflammation.

Max move

+102.4%

High of day $2.06

Sparker timei

7:03am ET

CNTB · Sep 30, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Connect Biopharma Holdings Ltd (Nasdaq: CNTB) announced positive preliminary topline data from its global Phase 2 study evaluating Rademikibart as an add-on treatment for acute exacerbations in adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 inflammation.

The study demonstrated promising results, indicating potential benefits of Rademikibart in this patient population. Further analysis and detailed results are expected to be released in the coming months.

As of the latest available data, Connect Biopharma has a free float of 15,434,718 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CNTB sparks.

Download Sniper App →

Catch the next CNTB-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →